Muscle fibers

 Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights

Retrieved on: 
Thursday, May 13, 2021

Gross proceeds of the offering, before deducting the underwriting discount and commissions and other estimated offering expenses, were $202.4 million.

Key Points: 
  • Gross proceeds of the offering, before deducting the underwriting discount and commissions and other estimated offering expenses, were $202.4 million.
  • In March 2021, EDG-5506 advanced into the Multiple Ascending Dose (MAD) portion of the study, having successfully completed the Single Ascending Dose (SAD) portion of the study.
  • The results build on previous reports and suggest that slow skeletal muscle fibers do not appear to leak muscle proteins associated with muscle injury and damage in DMD and BMD.
  • In February 2021, Edgewise also sponsored the Jett Foundation\xe2\x80\x99s Rare Disease Day Celebration.\nIn May 2021, Edgewise appointed Joanne Donovan, M.D., Ph.D., as its Chief Medical Officer (CMO), following her most recent tenure as CMO and Senior Vice President, Clinical Development at Catabasis Pharmaceuticals.